Model-Based Network Meta-Analysis: A Framework for Evidence Synthesis of Clinical Trial Data

Area of Science:

• Pharmacometrics
• Biostatistics
• Clinical Trial Design

Background:

• Model-based meta-analysis (MBMA) and network meta-analysis (NMA) are vital tools in drug development and healthcare decision-making.
• Current NMAs often fail to adequately incorporate dose-response relationships, treating doses independently or aggregating them.
• There is a need for advanced meta-analytic methods that can handle complex dose-response data within a network structure.

Purpose of the Study:

• To introduce a novel framework, model-based network meta-analysis (MBNMA), that combines MBMA and NMA.
• To develop a method that respects trial randomization while allowing for the estimation and prediction of effects across multiple agents and doses.
• To provide a flexible approach for incorporating plausible physiological dose-response models.

Main Methods:

• Developed a MBNMA framework integrating dose-response modeling within an NMA structure.
• Applied the framework to a dataset comparing triptan efficacy for migraine relief using a binary endpoint.
• The model is adaptable for various outcome types and complex dose-response relationships.

Main Results:

• The MBNMA framework successfully integrated dose-response information for multiple triptans.
• Demonstrated the ability to estimate and predict treatment effects across a range of doses.
• The approach respects randomization and provides a coherent estimation of relative treatment effects.

Conclusions:

• MBNMA offers a powerful and flexible approach for drug development and comparative effectiveness research.
• This method addresses limitations in current NMAs by effectively modeling dose-response relationships.
• MBNMA facilitates informed decision-making and optimized trial design by leveraging complex dose-response data.